Stay updated on Cabozantinib for Merkel Cell Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib for Merkel Cell Carcinoma Clinical Trial page.

Latest updates to the Cabozantinib for Merkel Cell Carcinoma Clinical Trial page
- Check7 days agoChange DetectedThe ClinicalTrials.gov record for a phase 2 cabozantinib study in recurrent or metastatic Merkel cell carcinoma is now displayed, including study design, participant criteria, and results. It indicates the trial was terminated for lack of accrual and is no longer recruiting.SummaryDifference47%

- Check14 days agoChange DetectedThe footer’s displayed site revision changed from v3.7.2 to v3.8.0; the study record remains inaccessible behind a 403 error.SummaryDifference0.2%

- Check21 days agoChange DetectedA sitewide NIH banner announces a transition from using “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs. The clinical trial details are not available on the page.SummaryDifference1%

- Check28 days agoChange DetectedThe footer revision number changed from v3.7.1 to v3.7.2 on the 403 error page.SummaryDifference0.2%

- Check34 days agoChange DetectedThe footer’s site revision number changes from v3.7.0 to v3.7.1 while the page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check56 days agoChange DetectedThe study record page now shows a 403 Forbidden error, replacing the usual content with an access-denied message. This prevents viewing the trial details and related information.SummaryDifference18%

Stay in the know with updates to Cabozantinib for Merkel Cell Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib for Merkel Cell Carcinoma Clinical Trial page.